Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1395-1404

  Sureda, A ^a   Arranz, R ^a   Iriondo, A ^a   Carreras, E ^a   Lahuerta, J J ^a   Garcia Conde, J ^a   Jarque, I ^a   Caballero, M D ^a   Ferraa C ^a   Lopez A ^a   Garcia Larana J ^a   Carrera, R ^a   Carrera, D ^a   Ruiz Romero, M D ^a   Leon A ^a   Rifon J ^a   Diaz Mediavilla, J ^a   Mataix, R ^a   Morey, M ^a   Moraleda, J M ^a   Altes A ^a   Lopez Guillermo A ^a   De la Serna, J ^a   Fernandez Ranada J M ^a   Sierra, J ^a   Conde, E ^a   more..

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; AUTOGRAFT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHILD; FEMALE; HODGKIN DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0035281922     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1395     Document Type: Article

References (54)

1. Twenty years of MOPP therapy for Hodgkin's disease
2. Combined modality therapy for advanced Hodgkin's disease: 15 Year follow-up data
3. Combination chemotherapy for advanced Hodgkin's disease in relapse following extensive radiotherapy
4. Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy
5. Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy
6. Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease
7. Development of effective salvage treatment programs for Hodgkin's disease: An ongoing challenge
8. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
9. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation
10. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
11. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients
12. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single center 8-year study of 155 patients
13. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant
14. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease for predicting outcome
15. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors
16. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
17. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors
18. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
19. Outcome of treatment of first relapse of Hodgkin's after primary chemotherapy: Identification of risks factors from the British Columbia experience 1970 to 1988
20. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
21. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNL1 randomised trial
22. High-dose therapy followed by hematopoietic stem transplantation for relapsed chemosensitive Hodgkin's disease: Final results of a randomized GHSG and EBMT trial (HD-R1)
23. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol
24. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: A retrospective study from the Spanish GELTAMO Cooperative Group
25. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: A retrospective analysis of 158 cases from the French registry
26. Report of the committee of Hodgkin's disease staging
27. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and inter-mediate-dose radiation therapy
28. Nonparametric estimation from incomplete estimations
29. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
30. Statistical aspects of the analysis of data from retrospective studies of disease
31. High-dose therapy and hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
32. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
33. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
34. Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow-up and analysis of prognostic factors
35. Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): Comparative results with two CBV regimens and importance of disease status at transplant
36. High dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: Results in 175 patients reported to the EBMT
37. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease
38. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study
39. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease
40. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
41. Autologous stem cell transplantation for high-risk Hodgkin's disease at a single institution: Improvement over time and impact of conditioning regimen
42. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
43. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
44. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's Lymphoma
45. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
46. Acute granulocytic leukemia, a complication of therapy in Hodgkin's disease?
47. Leukemia after therapy with alkylating agents for childhood cancer
48. Risk of second cancer after treatment for Hodgkin's disease
49. Increased risk of acute leukemia following extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease
50. Splenectomy in Hodgkin's disease and second leukaemias
51. Age related rejoining of broken chromosomes in human leukocytes following X-irradiation
52. A prognostic score for advanced Hodgkin's disease
53. Report of the EBMT registry of ABMT in Hodgkin's disease: Outcome in patients followed for at least three years
54. Treatment of advanced Hodgkin's disease with high-dose melphalan and autologous bone marrow transplantation